Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
32.49
+0.21 (0.66%)
NYSE · Last Trade: Mar 4th, 10:59 AM EST
Detailed Quote
Previous Close
32.28
Open
33.18
Bid
32.49
Ask
32.51
Day's Range
32.41 - 33.30
52 Week Range
12.47 - 37.35
Volume
2,796,004
Market Cap
36.08B
PE Ratio (TTM)
27.08
EPS (TTM)
1.2
Dividend & Yield
N/A (N/A)
1 Month Average Volume
8,372,347
Chart
About Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Teva Pharmaceutical Industries is a global leader in the pharmaceutical industry, specializing in the development, production, and marketing of a wide range of generic and specialty medications. The company is committed to improving patient access to high-quality medicines and focuses on therapeutic areas such as central nervous system disorders, pain management, respiratory diseases, and more. With a robust portfolio that includes both branded and generic products, Teva leverages its extensive research capabilities to innovate and provide solutions that meet the evolving healthcare needs of patients and healthcare professionals around the world. Read More
Duquesne Family Office's billionaire boss meaningfully pared down two high-flying stocks in the fourth quarter and made a $301 million wager on a popular sector-based exchange-traded fund (ETF).
PARSIPPANY, N.J. and CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and funds managed by Blackstone Life Sciences (“BXLS”) today announced a $400 million strategic funding agreement spread across four years to support the continued clinical development of duvakitug. Additionally, under the terms of the agreement, BXLS will be eligible for regulatory and commercial milestones as well as royalties on duvakitug worldwide sales.
As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent history, the company has spent the better part of the 2020s shedding the skin of its predecessor identities—Mylan and Pfizer’s Upjohn [...]
As of February 26, 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a defining crossroads. For years, the company was viewed by many on Wall Street as a "value trap"—a debt-laden giant formed from the 2020 merger of Mylan and Pfizer’s Upjohn division, struggling to find its footing in a deflationary generic drug market. However, [...]
PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in the upcoming investor conferences in March as follows:
The application was based on data from a late-stage trial in which TEV-'749 administered as a once-monthly subcutaneous injection demonstrated an efficacy and safety profile consistent with currently available olanzapine formulations.
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults. TEV-'749 is designed to improve real-world treatment adherence and help patients maintain long-term stability, with the goal of addressing a critical treatment gap for people living with schizophrenia.
February 10, 2026 Introduction As of February 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a pivotal juncture. Five years after its high-profile inception, the company has shed its skin as a debt-laden conglomerate of legacy brands to emerge as a leaner, more focused player in the specialty pharmaceutical space. For years, investors viewed Viatris [...]
As of January 28, 2026, Corcept Therapeutics (NASDAQ: CORT) stands at a critical crossroads that perfectly encapsulates the high-stakes nature of the biotechnology sector. Once a niche player focused solely on the rare endocrine disorder Cushing’s syndrome, Corcept has evolved into a diversified clinical-stage powerhouse. While the company recently weathered a significant regulatory storm involving [...]
NEW BRUNSWICK, N.J. — Johnson & Johnson (NYSE: JNJ) has officially closed the chapter on a year many analysts described as "transitional," reporting full-year 2025 earnings that met expectations while setting a bold trajectory for the year ahead. In its January 21, 2026, earnings call, the healthcare titan revealed it is
